Efficacy and safety of high-intensity focused ultrasound ablation under general anesthesia in older hepatocellular carcinoma patients.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
174 patients with HCC who underwent HIFU were enrolled in this study and divided into three age groups: <60 years (n=100), 60-74 years (n=55), and ≥75 years (n=19).
I · Intervention 중재 / 시술
HIFU were enrolled in this study and divided into three age groups: <60 years (n=100), 60-74 years (n=55), and ≥75 years (n=19)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
AFP ≥20 ng/mL was an independent risk factor ( = 0.016), whereas the combination of other local treatment methods was a protective factor ( = 0.016). [CONCLUSIONS] HIFU ablation under general anesthesia for older HCC patients is safe, feasible and effective.
[BACKGROUND] Older patients often have comorbidities, leading to a higher risk of delayed recovery while under general anesthesia.
- 표본수 (n) 100
APA
Xie S, Ran L, et al. (2025). Efficacy and safety of high-intensity focused ultrasound ablation under general anesthesia in older hepatocellular carcinoma patients.. Frontiers in oncology, 15, 1702332. https://doi.org/10.3389/fonc.2025.1702332
MLA
Xie S, et al.. "Efficacy and safety of high-intensity focused ultrasound ablation under general anesthesia in older hepatocellular carcinoma patients.." Frontiers in oncology, vol. 15, 2025, pp. 1702332.
PMID
41458596 ↗
Abstract 한글 요약
[BACKGROUND] Older patients often have comorbidities, leading to a higher risk of delayed recovery while under general anesthesia. High-intensity focused ultrasound (HIFU) for patients with hepatocellular carcinoma (HCC) usually requires general anesthesia to alleviate procedure-related pain and ensure immobilization. This study aimed to evaluate the safety and efficacy of HIFU for the treatment of older patients with HCC, and to explore the associated prognosis and risk factors.
[METHODS] A total of 174 patients with HCC who underwent HIFU were enrolled in this study and divided into three age groups: <60 years (n=100), 60-74 years (n=55), and ≥75 years (n=19). The risks of general anesthesia associated with HIFU were observed, and the ablation effects of HIFU were evaluated using contrast-enhanced CT or MRI. Survival analysis, prognosis and risk factors were analyzed.
[RESULTS] The prevalence of comorbidities was 73.68%, 52.72%, and 26.00% in patients aged ≥75 years, 60-74 years, and <60 years, respectively. The difference between the three groups was significant ( < 0.001). The rates of complete response (CR), partial response (PR), and ORR were 25.61%, 46.34%, and 71.95% in patients aged <60 years, 34.04%, 40.42%, and 74.46% in patients aged 60-74 years, and 12.50%, 62.50%, and 75.00% in patients aged ≥75 years, respectively. 1-year and 2-year overall survival (OS) rates in patients aged <60, 60-74, and ≥75 years were 78.4% and 70.5%, 84.5% and 75.3%, and 72.4% and 43.4%, respectively. There were no significant differences in ORR and OS between the three groups ( = 0.937 and 0.055, respectively). No significant difference of the median interval time of anesthesia recovery between three groups occurred ( = 0.208) and no other anesthesia-related complications were observed. CNLC stage III was an independent prognostic factor ( = 0.049). AFP ≥20 ng/mL was an independent risk factor ( = 0.016), whereas the combination of other local treatment methods was a protective factor ( = 0.016).
[CONCLUSIONS] HIFU ablation under general anesthesia for older HCC patients is safe, feasible and effective.
[METHODS] A total of 174 patients with HCC who underwent HIFU were enrolled in this study and divided into three age groups: <60 years (n=100), 60-74 years (n=55), and ≥75 years (n=19). The risks of general anesthesia associated with HIFU were observed, and the ablation effects of HIFU were evaluated using contrast-enhanced CT or MRI. Survival analysis, prognosis and risk factors were analyzed.
[RESULTS] The prevalence of comorbidities was 73.68%, 52.72%, and 26.00% in patients aged ≥75 years, 60-74 years, and <60 years, respectively. The difference between the three groups was significant ( < 0.001). The rates of complete response (CR), partial response (PR), and ORR were 25.61%, 46.34%, and 71.95% in patients aged <60 years, 34.04%, 40.42%, and 74.46% in patients aged 60-74 years, and 12.50%, 62.50%, and 75.00% in patients aged ≥75 years, respectively. 1-year and 2-year overall survival (OS) rates in patients aged <60, 60-74, and ≥75 years were 78.4% and 70.5%, 84.5% and 75.3%, and 72.4% and 43.4%, respectively. There were no significant differences in ORR and OS between the three groups ( = 0.937 and 0.055, respectively). No significant difference of the median interval time of anesthesia recovery between three groups occurred ( = 0.208) and no other anesthesia-related complications were observed. CNLC stage III was an independent prognostic factor ( = 0.049). AFP ≥20 ng/mL was an independent risk factor ( = 0.016), whereas the combination of other local treatment methods was a protective factor ( = 0.016).
[CONCLUSIONS] HIFU ablation under general anesthesia for older HCC patients is safe, feasible and effective.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- RST2G: Residual-Guided Spatiotemporal Transformer Graph Fusion Enhancement for Breast Cancer Segmentation in DCE-MRI.
- PREDICTOR: A Non-Enzymatic Catalytic Cascade Tool for in Situ Visualization of Small Extracellular Vesicle Surface glycoRNAs.
- Microbial modulators of the epigenome: probiotic regulation of MiRNAs and LncRNAs in health and disease and preventive medicine.
- Integrated single-cell and spatial transcriptomics uncover SPP1⁺ and HLA-DRB5⁺ macrophages as key modulators of the immune microenvironment in colorectal cancer liver metastasis.
- An integrated clinicopathological and genomic model for personalized prognosis in stage II-III colorectal cancer: a real-world study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.